The Longevity Podcast: Alzheimer's and Brain Health Research
AI-hosted deep dives into the latest Alzheimer's, dementia and brain health research, curated by Dr. Dung Trinh. Each episode breaks down a recent study or topic, such as diet, sleep, exercise, heart health, biomarkers, early detection and new treatments. We explain what the science says and what it may mean for staying sharp as we age.
Episodes are discussions generated with AI hosts. Every episode cites its sources so you can read the original research yourself. This podcast is for education only and is not medical advice. Talk with your doctor about your own health.
The Longevity Podcast: Alzheimer's and Brain Health Research
Brain Health as a Vital Sign: Lifestyle Steps Doctors Should Track
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Should doctors check brain health the way they check blood pressure? In this editorial, neurologist Gregory Cooper looks at the Brain Health Vital Signs project, which scores patients on 15 lifestyle risk factors for dementia. He explains how the FINGER, US POINTER, and LatAm-FINGERS trials showed that exercise, diet, mental challenge, social connection, and heart health can protect thinking skills, and why clinics now need practical ways to help patients with memory problems follow that advice.
Source: Cooper G, Is it time to make brain health a vital sign?, J Prev Alzheimers Dis 2026. https://doi.org/10.1016/j.tjpad.2026.100654 (CC BY 4.0)
This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice.
Never miss an episode—subscribe on your favorite podcast app!
Dementia Risk And A New Frame
SPEAKER_01Welcome to today's deep dive. Um, I want you to just think about your own life for a second. Yeah. Because you almost certainly know someone or you know, you love someone who has been affected by dementia. It's it's one of those deeply human experiences that just feels uh terrifyingly out of our hands.
SPEAKER_00Right. Like a like a genetic lottery we're all just hoping to win.
SPEAKER_01Exactly. But what if um what if nearly half of the global risk for cognitive decline is actually entirely within our control? And perhaps even more shockingly, what if our modern healthcare system is actively failing to help us manage that very risk?
SPEAKER_00Yeah, the gap between what modern science knows about brain health, you know, and what modern clinics are actually equipped to do about it, it's just one of the most profound contradictions in medicine today. I mean, we have the data, but we are completely missing the architecture to implement it.
SPEAKER_01Aaron Powell Which brings us right to the core of what we're unpacking for you today. So we're looking at a really brilliant 2026 editorial.
SPEAKER_00Aaron Powell From the Journal of Prevention of Alzheimer's disease, right?
SPEAKER_01Yes, exactly, by Gregory Cooper. And the title asks the central question perfectly. It's called, Is it time to make brain health a vital sign? Aaron Powell That's a great title.
SPEAKER_00It really sets the stage.
SPEAKER_01It totally does. So our mission in this deep dive is to explore why a single magic pill isn't going to solve the dementia crisis. We're gonna dig into the undeniable, biologically proven power of lifestyle interventions. Right. And uh we really need to figure out the surprising paradoxical reason why even the most highly motivated patients are just utterly failing to adopt brain-saving habits.
SPEAKER_00Aaron Powell Yeah, and to really grasp the gravity of Cooper's editorial, we we have to look at the sheer scale of the problem. I mean, the numbers are just staggering.
SPEAKER_01Aaron Powell Lay them out for us.
SPEAKER_00Okay, so right now, an estimated 55 million people are living with dementia worldwide. And based on current trends, that number is projected to skyrocket to uh 139 million by the year 2050.
SPEAKER_01Aaron Powell Wow. 139 million. I mean, that is that is a rising tide that will impact healthcare systems, economies, families, like on a scale we just haven't genuinely prepared for.
SPEAKER_00Aaron Powell No, not at all. And against that rising tide, we really have to evaluate the lifelines that modern medicine is currently, you know, throwing into the water.
Amyloid Antibodies And Their Limits
SPEAKER_01Trevor Burrus, Jr.: Right, the drugs.
SPEAKER_00Exactly. There's been this massive, well-deserved wave of excitement recently about amyloid targeting therapies or ATTs.
SPEAKER_01Aaron Powell The monoclonal antibodies.
SPEAKER_00Aaron Powell Right. They are designed to cross the blood-brain barrier and essentially clear out amyloid beta plaques. Those are the sticky proteins that build up and suffocate neurons in Alzheimer's disease.
SPEAKER_01Aaron Powell Which sounds amazing, obviously.
SPEAKER_00Aaron Powell It is. I mean, from a purely pharmacological standpoint, they represent a genuine breakthrough. But and this is where the editorial highlights a massive caveat. They come with a very strict indication.
SPEAKER_01Aaron Powell Right, because they are only approved for a very narrow window of patients, right?
SPEAKER_00Aaron Ross Powell Exactly. The indication is strictly for patients with mild cognitive impairment, which is known as MCI, due to Alzheimer's disease, or for patients in the very, very early mild stages of Alzheimer's.
SPEAKER_01So if you're outside that window, you're pretty much out of luck.
SPEAKER_00Treatment options outside of those specific parameters remain incredibly limited. It effectively leaves millions without any pharmacological options at all.
SPEAKER_01Aaron Ross Powell You know, reading through the biology of how these drugs actually work, the best way I could visualize it is this. Imagine these new ATTs are like a highly specialized world-class cleaning crew.
SPEAKER_00Aaron Powell Okay. I like this.
SPEAKER_01Right. So they are phenomenal at sweeping up the ash and the smoke damage inside a burning house, which, in this case, is the amyloid plaque in the brain. But if the house is still actively on fire because of, I don't know, a lifetime of severe metabolic and vascular dysfunction. Trevor Burrus, Jr.
SPEAKER_00Sweeping up the ash isn't going to save the kitchen.
SPEAKER_01Aaron Ross Powell Exactly. It won't save the structural integrity of the house. And worse, they only agree to clean the house if the fire just started. If the fire has already spread to the living room, or if it's an electrical fire instead of a grease fire, that multi-million dollar cleaning crew just packs up and leaves.
SPEAKER_00Aaron Powell That is the underlying fire in that scenario is the perfect way to look at it. Because if we connect this to the bigger picture, this incredibly narrow window for treatment leaves countless patients entirely ineligible for help.
SPEAKER_01Which is terrifying.
SPEAKER_00It is. We are essentially watching a massive portion of that projected 139 million people fall right through the cracks of modern pharmaceutical medicine. I mean, we simply cannot medicate our way out of a crisis this large with the highly specific tools we currently possess.
SPEAKER_01Yeah, if these multi-million dollar drugs are only patching a tiny leak in a sinking ship, science naturally had to, you know, look at what was causing the flood in the first place.
SPEAKER_00Exactly.
The 45 Percent We Can Change
SPEAKER_01Okay, let's unpack this because the data on lifestyle modifications is where this conversation gets incredibly hopeful. And it's where the editorial points to some massive revelations from the Lancet Commission.
SPEAKER_00Right. So the Lancet Commission periodically updates this definitive list of modifiable risk factors for dementia. And currently they have identified 14 specific modifiable risk factors. Yes. And the critical takeaway here is that these 14 factors account for approximately 45% of the risk of dementia worldwide.
SPEAKER_01Wow. Wait, really? Nearly half?
SPEAKER_00Nearly half.
SPEAKER_01That totally reframes dementia. You know, it moves it from being this inevitable consequence of aging to something that is largely preventable. Completely. And what fascinated me in the sources is how these specific factors physically alter the brain. Like we aren't just talking about generic uh eat healthy advice from a high school health class.
SPEAKER_00No, not at all. The biological mechanisms are deeply, deeply interconnected. Take hearing loss, for example.
SPEAKER_01Aaron Powell Right, which is one of the 14 factors.
SPEAKER_00Exactly. When you lose your hearing, you aren't just losing sound, you are severely reducing the cognitive load on your brain. The brain has to work so much harder to process garbled audio, which essentially steals resources from memory formation.
SPEAKER_01Oh wow. I never thought about it like that.
SPEAKER_00And simultaneously, the lack of auditory input often leads to social isolation. And social isolation itself reduces cognitive reserve, which is the brain's ability to improvise and find alternate neural pathways. Trevor Burrus, Jr.
SPEAKER_01It's a vicious cycle.
SPEAKER_00It really is. Or look at hypertension and air pollution. Both of those cause microvascular damage. They physically degrade the tiny blood vessels in the brain.
SPEAKER_01Aaron Powell Which impairs the brain's ability to naturally flush out that daily amyloid buildup we were just talking about, right?
SPEAKER_00Trevor Burrus Exactly. It's all connected to the brain's physical infrastructure.
SPEAKER_01Aaron Ross Powell And this isn't just theoretical modeling anymore. I mean the editorial traces over a decade of hard clinical trials proving that targeting these factors actually maintains cognition.
SPEAKER_00Aaron Powell Yeah, the momentum really started with the 2015 finger study out of Finland.
SPEAKER_01Aaron Powell The Finger Study.
SPEAKER_00Right. So they took an at-risk elderly population and implemented what they call a multidomain intervention. They basically combined specific diets, physical exercise, cognitive training, social engagement, and rigorous vascular risk monitoring.
SPEAKER_01All at the same time. And the scientific community didn't just, you know, stop in Finland and call it a day.
SPEAKER_00Aaron Powell No, the replication of that data is what makes it so robust. Fast forward to the 2025 U.S. Pointer study, which successfully replicated those exact findings in a highly diverse United States population.
SPEAKER_01Awesome.
SPEAKER_00And then a year later, in 2026, the Latam Finger study confirmed the cognitive benefits across an ethnically diverse population down in Latin America. I mean, we have over a decade of global, irrefutable clinical data, proving that lifestyle is, in fact,
Why Guided Programs Work Better
SPEAKER_00medicine.
SPEAKER_01Aaron Powell But hold on, let me play devil's advocate for a second. When we talk about interventions in these studies, are we just talking about a doctor handing a 75-year-old patient a glossy pamphlet at the end of a 15-minute checkup?
SPEAKER_00Right. Like, here you go, good luck.
SPEAKER_01Yeah. Something that just says eat a few more salads, do the Sunday crossword puzzle, and try to take a walk. Because I mean, if that is all it takes, it seems like we wouldn't be staring down 139 million cases by 2050.
SPEAKER_00That is such a crucial point.
SPEAKER_01Aaron Powell And the U.S. Pointer study specifically addressed that exact distinction. It's a vital one.
SPEAKER_00Aaron Powell Okay. How so?
SPEAKER_01They randomized patients into two arms. One group received education and a self-guided intervention, basically the pamphlet approach you just mentioned.
SPEAKER_00Okay.
SPEAKER_01The other group was placed into a strictly guided program. They had structured support for exercise, diet, cognitive challenges, and cardiovascular monitoring.
SPEAKER_00And the biological outcomes reflected that structural difference?
SPEAKER_01Aaron Powell Distinctly.
SPEAKER_00Aaron Ross Powell I mean, while both groups showed some improvement over their baseline, which proves that simply having the knowledge does help, the patients in the guided arm showed statistically significant greater improvements in global cognition.
SPEAKER_01So they really needed that hands-on help.
SPEAKER_00Exactly. The structured support, the accountability, and the active management of actually removing friction from their daily lives, those were the catalysts for actual neurological improvement.
SPEAKER_01Okay, here's where it gets really interesting. Because if we have 10 years of global data proving that these guided lifestyle changes work, you would naturally assume something. Right. You'd assume that patients who are currently sitting in specialized memory clinics, people actively facing the terrifying reality of cognitive decline, would be rigorously following these protocols. You'd think they'd be doing everything in their power to manage those 14 risk factors.
SPEAKER_00You would certainly think so.
SPEAKER_01Aaron Powell But the editorial highlights a new study that proves the exact opposite is happening.
The 3 Percent Compliance Shock
SPEAKER_00Yeah, this is where the editorial brings our attention to a newly published report by Daphner and his colleagues. It's uh regarding the Brain Health Vital Science Project, or BHVS.
SPEAKER_01Aaron Powell The BHVS, okay.
SPEAKER_00Aaron Powell So the researchers developed this brilliant way to quantify these lifestyle habits. They created a BHVS score that grades patients on a scale of zero to two across 15 different lifestyle risk factors.
SPEAKER_01It's like a literal vital sign for your daily habits. I mean, think about your own morning routine. They are tracking things like whether you are actually getting 150 minutes of zone two cardio a week.
SPEAKER_00Exactly. Your adherence to a Mediterranean-style diet, your sleep quality, your A1C levels.
SPEAKER_01They are essentially turning behavior into measurable clinical data.
SPEAKER_00Aaron Ross Powell Exactly that. And to see how well patients were complying, the researchers looked at two different populations within their clinic. On one side, they had patients actively pursuing those complex amyloid targeting therapies.
SPEAKER_01The antibody infusions.
SPEAKER_00Right. They hypothesized that these specific patients would show a very high level of compliance with a brain healthy lifestyle. Trevor Burrus, Jr.
SPEAKER_01Which makes total logical sense. I mean, if you are a patient motivated enough to seek out experimental cutting-edge antibody infusions, I mean a process that involves frequent clinic visits, MRI scans, and the potential risk of brain bleeding.
SPEAKER_00You are obviously highly motivated. Trevor Burrus, Jr.
SPEAKER_01Right. You are highly motivated to save your cognition. You would naturally assume that person is also, you know, eating salmon, going for brisk walks, and managing their blood pressure.
SPEAKER_00Aaron Powell Well, the data revealed something completely different. Oh boy. They compared that highly motivated ATT group to patients in a general cognitive neurology clinic, which included non-Alzheimer's dementia. And across both groups, they found incredibly low levels of compliance.
SPEAKER_01How low is incredibly low?
SPEAKER_00Aaron Ross Powell Less than 3% of the patients were successfully following the recommendations for all 15 items in the Brain Health Vital Sign Score.
SPEAKER_01Aaron Powell Less than 3%? I mean, that is practically a rounding error.
SPEAKER_00Aaron Ross Powell It really is.
SPEAKER_01That means 97% of these patients who are sitting in a memory clinic, actively worried about losing their minds, are failing to implement the very lifestyle changes biologically proven to protect them.
SPEAKER_00Yeah. What's fascinating here is the psychological and systemic paradox it exposes. You have patients willing to navigate incredibly complex medical hurdles to receive advanced pharmacological treatments.
SPEAKER_01Right.
SPEAKER_00Yet they're failing to implement the fundamental, everyday behavioral changes that we know account for nearly half of the global dementia risk. It is a massive disconnect between medical motivation and behavioral reality.
SPEAKER_01And the immediate, you know, knee-jerk reaction when you hear a 3% compliance rate is to just blame the patient. You think, well, they just don't care enough or they're too lazy to change.
SPEAKER_00Aaron Powell It's the easy answer. Trevor Burrus, Jr.
SPEAKER_01Right. But how do we actually explain this massive disconnect without just pointing fingers at people who are already suffering?
SPEAKER_00Aaron Powell Well, the study did provide several surface level barriers for this low adherence. Things like a lack of knowledge, severe time constraints, financial limitations, and suboptimal medical management of their underlying cardiovascular conditions.
SPEAKER_01Aaron Powell Which are all valid barriers. But there was one highly specific detail from the text that completely reframed this for me.
SPEAKER_00Aaron Powell Oh, about the cognitive impairment itself?
SPEAKER_01Yes. When you are dealing with a memory clinic, you might assume that the cognitive impairment itself is the main barrier. You might think, well, they have dementia. Of course they can't remember to follow a complex new diet or exercise routine.
SPEAKER_00Aaron Powell It seems like a logical assumption.
SPEAKER_01Aaron Powell But the study noted there was absolutely no difference in adherence between the patients who only had mild cognitive impairment and the patients who already had mild dementia. The cognitive decline wasn't the culprit.
SPEAKER_00Aaron Powell Not at all. The real barrier, as the researchers noted, is deeply ingrained lifelong habits that predate the onset of the cognitive impairment entirely.
SPEAKER_01Ah, right.
SPEAKER_00These lifestyle factors, such as diet, exercise, vascular health, they are known risk factors precisely because they compound over a lifetime. I mean, if someone has spent 50 years not exercising, eating highly processed foods, and sleeping poorly.
SPEAKER_01The sudden diagnosis isn't going to fix that.
SPEAKER_00Exactly. The sudden diagnosis of a cognitive issue isn't going to magically rewire half a century of behavioral conditioning overnight.
SPEAKER_01Yeah, because sitting in an infusion chair to receive an antibody drug is passive. Changing a 50-year-old diet requires active, relentless, daily effort. Which brings us to the real target of the editorial's critique.
Fixing The System Not Patients
SPEAKER_01It's not the patient who is failing.
SPEAKER_00No, we really have to synthesize this data and shift the lens from the individual to the healthcare system itself. This 3% compliance rate represents a massive systemic failure.
SPEAKER_01Totally.
SPEAKER_00Think about how specialty clinics are designed today. They are brilliantly optimized to evaluate a patient, arrive at a complex diagnosis, and administer highly complex pharmacological interventions.
SPEAKER_01Right. An immense amount of capital and infrastructure has gone into the creation of systems to administer these new ATT drugs safely.
SPEAKER_00Absolutely.
SPEAKER_01We are talking about millions of dollars, specialized infusion centers, massive administrative protocols, and like dedicated staff just to deliver the drug.
SPEAKER_00Meanwhile, absolutely nothing comparable has been built to administer, track, or support lifestyle changes. We have built a multi-billion dollar machine optimized purely for pharmacology, and we act surprised when it fails at behavioral psychology. It's so backward. This raises an important question. Are we setting patients up to fail by investing all of our systemic resources into drug delivery infrastructure while entirely ignoring the systemic guided support required to actually change human behavior?
SPEAKER_01So, what does this all mean?
SPEAKER_00If we have a systemic failure, we clearly need a systemic solution. How do we actually fix the machine? Well, the editorial doesn't just point out the flaws, it offers a roadmap for making brain health a true, actionable vital sign.
SPEAKER_01But just looking at the logistics of that, there's a practical hurdle right out of the gate, right? Yeah. The text notes that while tracking these brain health vital signs over time is a fantastic idea conceptually, actually doing it right now requires extracting a massive amount of fragmented laboratory data from electronic health records. And for anyone who has ever worked in a clinic, you know that can be an incredibly cumbersome, time-consuming nightmare.
SPEAKER_00Aaron Powell Oh, the administrative burden is a very real bottleneck. But the editorial argues that overcoming this burden is necessary, and they outline specific structural solutions.
SPEAKER_01Aaron Powell What kind of solutions?
SPEAKER_00They are calling for the development and rigorous study of interventions designed specifically to improve adherence to the BHVS. For instance, they want to see a much more robust use of patient navigation systems.
SPEAKER_01Like caseworkers?
SPEAKER_00Essentially, yes. Navigators who help remove the daily friction for these patients. They are also pushing for dedicated community outreach, intensive educational programming, and forging much stronger, integrated partnerships with primary care physicians.
SPEAKER_01Okay, so it's essentially taking the guided part of the U.S. Pointer study and institutionalizing it across the entire healthcare network.
SPEAKER_00Aaron Powell Exactly. And this is particularly vital for healthcare systems engaged in value-based care.
unknownTrevor Burrus, Jr.
SPEAKER_01Right. Those are the models where providers are compensated based on long-term patient health outcomes rather than just the sheer volume of services provided.
SPEAKER_00Aaron Powell Precisely. The editorial strongly argues that it is time for these systems to vastly increase their investment in developing effective, tangible, individualized interventions for those modifiable risk factors.
SPEAKER_01It really is a complete paradigm shift.
SPEAKER_00It requires an entirely new framework, which the editorial describes as tertiary prevention.
SPEAKER_01Tertiary prevention. Okay, break that down for us.
SPEAKER_00It means actively managing a disease post-diagnosis to slow or stop its progression through lifestyle rather than just waiting for the decline. Creating this infrastructure means treating the prescription of a daily walk and a vascular healthy diet with the exact same rigorous, system-wide investment and tracking as we do the prescription of an advanced antibody infusion.
Start Brain Health Tracking Earlier
SPEAKER_01Man, we've covered a lot of ground today.
SPEAKER_00We really have.
SPEAKER_01We started by looking at the incredible but ultimately very strictly limited biological promise of the new Alzheimer's drugs. We saw how they only apply to a narrow window of patients and only address a fraction of the underlying pathology. Right. Then we pivoted to the undeniable scientifically proven power of multidomain lifestyle changes, factors like sleep, hearing, and vascular health, which, again, account for nearly 45% of our global risk. It's huge. But finally, we had to confront the harsh reality exposed by the Daphner study. Simply knowing what to do is practically useless without a healthcare system actually designed and funded to help you change your lifelong habits. We are currently failing patients by treating lifestyle as a glossy pamphlet rather than a vital sign.
SPEAKER_00Aaron Powell It is a critical moment of realization for modern neurology and preventative medicine. I mean, the data we receive in the coming years from the Brain Health Vital Science Project will be essential. It'll show us if we can actually build the systems necessary to turn this ship around before we hit that 139 million mark.
SPEAKER_01Absolutely. So I want to leave you with a final thought to mull over as you go about your day. And it builds right off the reality of those deeply ingrained habits we discussed.
SPEAKER_00Okay.
SPEAKER_01If the Daphner study showed that our inability to adopt brain healthy habits in our 70s and 80s is rooted in lifelong patterns established long before cognitive decline begins, should we stop treating brain health as a geriatric issue entirely?
SPEAKER_00Well, that's interesting.
SPEAKER_01Imagine if your brain health vital sign was measured starting in your 20s, right alongside your blood pressure and your heart rate. If we started building the infrastructure to intervene when those behavioral habits are just forming, how drastically could we change the trajectory of those projected dementia cases by 2050?
SPEAKER_00That's a powerful thought.
SPEAKER_01It really makes you wonder how differently we'd live if our doctors tracked our habits as closely as our prescriptions. Thank you so much for joining us for this deep dive. Stay curious, keep asking the hard questions, and we will catch you next time.